NCT07583784Recruiting
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 860 (estimated)
- First submitted
- 7 May 2026
- Start date
- 26 Aug 2026
- Primary completion date
- 31 Dec 2031
- Lead sponsor
- Chonnam National University Hospital
- NCT number
- NCT07583784
What you commit to
- Study type: Interventional
- Planned participants: 860
- From 26 Aug 2026 to the primary completion date, 31 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of intracranial hemorrhage
Other illness
- Planned cardiac surgery within 1 year after randomization
- Coexisting conditions related to high risk of life-threatening bleeding
- Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Lab values
- Advanced chronic kidney disease (creatinine clearance \<15 ml/min/1.73 m2) or on dialysis
Other
- Patients contraindicated for use of DOACs or clopidogrel
- Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist
- Patients with severe thrombocytopenia or coagulopathy
- Liver cirrhosis or severe hepatic dysfunction
- Pregnancy or breast feeding
- Unwillingness or inability to comply with the procedures described in this protocol.
Who the study is looking for
- Patients aged 19 years old
- Patients with AF and CHA2DS2-VA score ≥2.
- ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)
- STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12
- NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12
- Symptoms of ischemia.
- New or presumed new significant ST-T wave changes
- Development of pathological Q waves on electrocardiography.
- Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
- Intracoronary thrombus detected on angiography.
- Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chonnam National University Hospital Coordinator of this site? Confirm its status | Gwangju | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.